Therapeutic implications of advances in our understanding of transitional B-cell development in humans

Expert Review of Clinical Immunology

Volumn 6, Issue 5, 2010, Pages 765-775

  Suryani, Santi ^a,b   Tangye, Stuart G ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

autoimmunity; B cell development; human B cells; immunodeficiency; therapeutics; transitional B cells

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B7 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD5 ANTIGEN; CD81 ANTIGEN; CD86 ANTIGEN; CD9 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR7; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; FAS ANTIGEN; GLOBOTRIAOSYLCERAMIDE; HERMES ANTIGEN; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; INTERLEUKIN 7; LYMPHOID ENHANCER FACTOR 1; PROTEIN BCL 2; STAT3 PROTEIN;

AUTOIMMUNITY; B LYMPHOCYTE DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL SUBPOPULATION; CLONAL ANERGY; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; PHENOTYPE; PRE B LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SPECIES COMPARISON;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; BIOMEDICAL RESEARCH; CELL DIFFERENTIATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MICE; MUTATION;

EID: 77956497340     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.55     Document Type: Review

References (103)

1. Cunningham-Rundles C, Ponda PP. Molecular defects in T-and B-cell primary immunodefciency diseases. Nat. Rev. Immunol. 5(11), 880-892 (2005).
2. Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res. Ther. 11(5), 247 (2009).
3. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20(5), 517-527 (2004).
4. Notarangelo LD. Primary immunodefciencies. J. Allergy Clin. Immunol. 125(2 Suppl. 2), S182-S194 (2010).
5. Notarangelo LD, Fischer A, Geha RS et al. Primary immunodefciencies: 2009 update. J. Allergy Clin. Immunol. 124(6), 1161-1178 (2009).
6. Tangye SG, Tarlinton DM. Memory B cells: effectors of long-lived immune responses. Eur. J. Immunol. 39(8), 2065-2075 (2009).
7. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5(7), 564-576 (2006).
8. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6(5), 394-403 (2006).
9. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 24, 467-496 (2006).
10. Lai AY, Kondo M. T and B lymphocyte differentiation from hematopoietic stem cell. Semin. Immunol. 20(4), 207-212 (2008).
11. Hardy RR, Hayakawa K. B cell development pathways. Annu. Rev. Immunol. 19, 595-621 (2001).
12. Monroe JG, Dorshkind K. Fate decisions regulating bone marrow and peripheral B lymphocyte development. Adv. Immunol. 95, 1-50 (2007).
13. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435(7042), 590-597 (2005).
14. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 301(5638), 1374-1377 (2003).
15. Wardemann H, Nussenzweig MC. B-cell self-tolerance in humans. Adv. Immunol. 95, 83-110 (2007).
16. Carsetti R, Kohler G, Lamers MC. Transitional B cells are the target of negative selection in the B cell compartment. J. Exp. Med. 181(6), 2129-2140 (1995).
17. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards immune competence. Trends Immunol. 24(6), 343-349 (2003).
18. Loder F, Mutschler B, Ray RJ et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J. Exp. Med. 190(1), 75-89 (1999).
19. Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J. Immunol. 167(12), 6834-6840 (2001).
20. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol. Rev. 197, 179-191 (2004).
21. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identifcation and characterization of circulating human transitional B cells. Blood 105(11), 4390-4398 (2005).
22. Cuss AK, Avery DT, Cannons JL et al. Expansion of functionally immature transitional B cells is associated with human-immunodefcient states characterized by impaired humoral immunity. J. Immunol. 176(3), 1506-1516 (2006).
23. Suryani S, Fulcher DA, Santner-Nanan B et al. Differential expression of CD21 identifes developmentally and functionally distinct subsets of human transitional B cells. Blood 115(3), 519-529 (2010).
24. Anolik JH, Friedberg JW, Zheng B et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin. Immunol. 122(2), 139-145 (2007).
25. Palanichamy A, Barnard J, Zheng B et al Novel human transitional B cell populations revealed by B cell depletion therapy. J. Immunol. 182(10), 5982-5993 (2009).
26. + pre-naive B cell population. J. Immunol. 182(7), 4116-4126 (2009).
27. Hystad ME, Myklebust JH, Bo TH et al. Characterization of early stages of human B cell development by gene expression profling. J. Immunol. 179(6), 3662-3671 (2007).
28. Avery DT, Deenick EK, Ma CS et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207(1), 155-171 (2010).
29. Ho J, Moir S, Malaspina A et al. Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. Proc. Natl Acad. Sci. USA 103(51), 19436-19441 (2006).
30. Storek J, Saxon A. Reconstitution of B cell immunity following bone marrow transplantation. Bone Marrow Transplant. 9(6), 395-408 (1992).
31. Antin JH, Ault KA, Rappeport JM, Smith BR. B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defnes a distinct population of B lymphocytes. J. Clin. Invest. 80(2), 325-332 (1987).
32. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short-and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res. Ther. 11(4), R123 (2009).
33. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54(2), 613-620 (2006).
34. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54(8), 2377-2386 (2006).
35. Yurasov S, Wardemann H, Hammersen J et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201(5), 703-711 (2005).
36. Yurasov S, Tiller T, Tsuiji M et al. Persistent expression of autoantibodies in SLE patients in remission. J. Exp. Med. 203(10), 2255-2261 (2006).
37. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32(1), 129-140 (2010).
38. Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune infammation by the induction of regulatory B cells. Proc. Natl Acad. Sci. USA 104(35), 14080-14085 (2007).
39. + phenotype controls T cell-dependent infammatory responses. Immunity 28(5), 639-650 (2008).
40. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118(10), 3420-3430 (2008).
41. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and infammation. Immunol. Rev. 224, 201-214 (2008).
42. Llorente L, Richaud-Patin Y, Wijdenes J et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur. Cytokine Netw. 4(6), 421-427 (1993).
43. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol. 2(7), 465-475 (2002).
44. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231-264 (2003).
45. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin. Immunol. 18(5), 305-317 (2006).
46. Kalled SL. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 18(5), 290-296 (2006).
47. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J. Clin. Invest. 119(5), 1066-1073 (2009).
48. O'Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199(1), 91-98 (2004).
49. Avery DT, Kalled SL, Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112(2), 286-297 (2003).
50. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109(1), 59-68 (2002).
51. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44(6), 1313-1319 (2001).
52. Lesley R, Xu Y, Kalled SL et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20(4), 441-453 (2004).
53. Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20(6), 785-798 (2004).
54. Wallace DJ, Stohl W, Furie RA et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61(9), 1168-1178 (2009).
55. Jacobi AM, Huang W, Wang T et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a Phase II, double-blind, placebo-controlled, dose-ranging study Arthritis Rheum. 62(1), 201-210 (2010).
56. Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr. Opin Rheumatol. 22(5), 504-509 (2010).
57. Baker KP, Edwards BM, Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48(11), 3253-3265 (2003).
58. Vugmeyster Y, Seshasayee D, Chang W et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am. J. Pathol. 168(2), 476-489 (2006).
59. Batten M, Groom J, Cachero TG et al BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192(10), 1453-1466 (2000).
60. Warnatz K, Salzer U, Rizzi M et al. B-cell activating factor receptor defciency is associated with an adult-onset antibody defciency syndrome in humans. Proc. Natl Acad. Sci. USA 106(33), 13945-13950 (2009).
61. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J. Immunol. 179(11), 7276-7286 (2007).
62. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profles of adhesion molecule expression. Blood 99(6), 2154-2161 (2002).
63. Hoyer BF, Moser K, Hauser AE et al Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199(11), 1577-1584 (2004).
64. Namen AE, Lupton S, Hjerrild K et al Stimulation of B-cell progenitors by cloned murine interleukin-7 Nature 333(6173), 571-573 (1988).
65. Noguchi M, Nakamura Y, Russell SM et al. Interleukin-2 receptor g chain: a functional component of the interleukin-7 receptor. Science 262(5141), 1877-1880 (1993).
66. Sudo T, Ito M, Ogawa Y et al. Interleukin 7 production and function in stromal cell-dependent B cell development. J. Exp. Med. 170(1), 333-338 (1989).
67. Sudo T, Nishikawa S, Ohno N et al. Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc. Natl Acad. Sci. USA 90(19), 9125-9129 (1993).
68. Grabstein KH, Waldschmidt TJ, Finkelman FD et al. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J. Exp. Med. 178(1), 257-264 (1993).
69. Peschon JJ, Morrissey PJ, Grabstein KH et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-defcient mice. J. Exp. Med. 180(5), 1955-1960 (1994).
70. Von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifes IL-7 as a nonredundant cytokine. J. Exp. Med. 181(4), 1519-1526 (1995).
71. Prieyl JA, LeBien TW. Interleukin 7 independent development of human B cells. Proc. Natl Acad. Sci. USA 93(19), 10348-10353 (1996).
72. + severe combined immunodefciency. Nat. Genet. 20(4), 394-397 (1998).
73. Roifman CM, Zhang J, Chitayat D, Sharfe N. A partial defciency of interleukin-7R a is suffcient to abrogate T-cell development and cause severe combined immunodefciency. Blood 96(8), 2803-2807 (2000).
74. Giliani S, Mori L, de Saint Basile G et al. Interleukin-7 receptor a (IL-7Ra) defciency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients. Immunol. Rev. 203, 110-126 (2005).
75. Noguchi M, Yi H, Rosenblatt HM et al. Interleukin-2 receptor g chain mutation results in X-linked severe combined immunodefciency in humans. Cell 73(1), 147-157 (1993).
76. Russell SM, Tayebi N, Nakajima H et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270(5237), 797-800 (1995).
77. Macchi P, Villa A, Giliani S et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune defciency (SCID). Nature 377(6544), 65-68 (1995).
78. Parrish YK, Baez I, Milford TA et al. IL-7 dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J. Immunol. 182(7), 4255-4266 (2009).
79. Johnson SE, Shah N, Panoskaltsis-Mortari A, LeBien TW. Murine and human IL-7 activate STAT5 and induce proliferation of normal human pro-B cells. J. Immunol. 175(11), 7325-7331 (2005).
80. Saeland S, Duvert V, Pandrau D et al Interleukin-7 induces the proliferation of normal human B-cell precursors. Blood 78(9), 2229-2238 (1991).
81. Duty JA, Szodoray P, Zheng NY et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J. Exp. Med. 206(1), 139-151 (2009).
82. Isnardi I, Ng YS, Menard L et al. Complement receptor 2/CD21-negative human naive B cells mostly contain autoreactive unresponsive clones. Blood 115(24), 5026-5036 (2010).
83. low B cells in common variable immunodefciency resemble tissue homing, innate-like B cells. Proc. Natl Acad. Sci. USA 106(32), 13451-13456 (2009).
84. +IgM-IgD) in subgroups of patients with common variable immunodefciency: a new approach to classify a heterogeneous disease. Blood 99(5), 1544-1551 (2002).
85. + T cells. J. Clin. Invest. 115(4), 1049-1059 (2005).
86. +, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. J. Clin. Invest. 116(2), 322-333 (2006).
87. Weller S, Faili A, Garcia C et al. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversifcation pathway in humans. Proc. Natl Acad. Sci. USA 98(3), 1166-1170 (2001).
88. Jain A, Ma CA, Lopez-Granados E et al. Specifc NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation. J. Clin. Invest. 114(11), 1593-1602 (2004).
89. Warnatz K, Bossaller L, Salzer U et al. Human ICOS defciency abrogates the germinal center reaction and provides a monogenic model for common variable immunodefciency. Blood 107(8), 3045-3052 (2006).
90. Van Zelm MC, Reisli I, van der Burg M et al. An antibody-defciency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354(18), 1901-1912 (2006).
91. Kanegane H, Agematsu K, Futatani T et al. Novel mutations in a Japanese patient with CD19 defciency. Genes Immun. 8(8), 663-670 (2007).
92. Speckmann C, Enders A, Woellner C et al. Reduced memory B cells in patients with hyper IgE syndrome. Clin. Immunol. 129(3), 448-454 (2008).
93. Nurieva RI, Chung Y, Hwang D et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29(1), 138-149 (2008).
94. Van Zelm MC, Smet J, Adams B et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody defciency. J. Clin. Invest. 120(4), 1265-1274 (2010).
95. Kuijpers T W, Bende RJ, Baars PA et al. CD20 defciency in humans results in impaired T cell-independent antibody responses. J. Clin. Invest. 120(1), 214-222 (2010).
96. low B cells in common variable immunodefciency resemble tissue homing, innate-like B cells. Proc. Natl Acad. Sci. USA 106(32), 13451-13456 (2009).
97. Darce JR, Arendt BK, Chang SK, Jelinek DF. Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells. J. Immunol. 178(9), 5612-5622 (2007).
98. Ellyard JI, Avery DT, Mackay CR, Tangye SG. Contribution of stromal cells to the migration, function and retention of plasma cells in human spleen: potential roles of CXCL12, IL-6 and CD54. Eur. J. Immunol. 35(3), 699-708 (2005).
99. Ellyard JI, Avery DT, Phan TG, Hare NJ, Hodgkin PD, Tangye SG. Antigen-selected, immunoglobulin-secreting cells persist in human spleen and bone marrow. Blood 103(10), 3805-3812 (2004).
100. Wolniak KL, Noelle RJ, Waldschmidt TJ. Characterization of (4-hydroxy-3-nitrophenyl)acetyl (NP)-specifc germinal center B cells and antigen-binding B220-cells after primary NP challenge in mice. J. Immunol. 177(4), 2072-2079 (2006).
101. Kallies A, Hasbold J, Tarlinton DM et al. Plasma cell ontogeny defned by quantitative changes in blimp-1 expression. J. Exp. Med. 200(8), 967-977 (2004).
102. Tangye SG, Liu YJ, Aversa G, Phillips JH, de Vries JE. Identifcation of functional human splenic memory B cells by expression of CD148 and CD27. J. Exp. Med. 188(9), 1691-1703 (1998).
103. Liu YJ, Barthelemy C, Debouteiller O, Arpin C, Durand I, Banchereau J. Memory B-cells from human tonsils colonize mucosal epithelium and directly present antigen to T-cells by rapid up-regulation of B7-1 and B7-2. Immunity 2(3), 239-248 (1995).